R&D channel feed – Endpoints News

R&D channel feed

Pfizer partner Opko reports a PhIII failure for growth hormone, but tries to steer out of a crash

9 years ago

In back-to-back disasters, the FDA spurns Innocoll’s NDA and shares plunge (again)

9 years ago

Faced with a dilemma, the FDA rejects Cempra's antibiotic, demands big safety study

9 years ago

In back-to-back failures, Anthera’s CF drug Sollpura falls short in PhIII, shares crater (again)

9 years ago

Seattle Genetics stock tumbles after 4 deaths force the FDA to slap a clinical hold on AML drug

9 years ago

Merck’s Ebola vaccine promises to stop the next outbreak in its tracks

9 years ago

Bial accused of negligence in lethal drug trial — Nature

9 years ago

Roche readies a hunt for marketing OK on hemophilia blockbuster hopeful emicizumab after PhIII success

9 years ago

Alexion adds a failed pivotal Soliris trial to an air of crisis. The perfect time to talk buyout

9 years ago

Galapagos, AbbVie glimpse early progress in search of a cystic fibrosis triple to rival Vertex

9 years ago

Merrimack shutters a failing PhII breast cancer study for MM-302

9 years ago

Acadia shares skid as Nuplazid clears mid-stage hurdle for Alzheimer’s psychosis, but skeptics pounce

9 years ago

Akebia forges $1B US pact with Otsuka on lead drug for CKD, shares spike

9 years ago

Watch out Gilead, GSK’s ViiV is steaming ahead with promising late-stage data on a two-drug HIV therapy

9 years ago

Microcap Conatus teams up with pharma giant Novartis on NASH drug, shares rocket up

9 years ago

After an R&D odyssey filled with setbacks, Clovis wins an FDA OK for rucaparib

9 years ago

Ionis reports a positive PhIII for volanesorsen in rare metabolic disorders

9 years ago

Yes, Loxo is still planning on seeking an accelerated OK, in case you had forgotten

9 years ago

Xtandi fails a combo study, blocking a path to continued use for Pfizer, Astellas

9 years ago

INC Research promises 550 new jobs as it plots headquarters move

9 years ago

Bristol-Myers outlines a big R&D overhaul covering East, West Coast operations

9 years ago

Kyowa Hakko Kirin hit with a new PhIII setback on an old Parkinson’s drug

9 years ago

GSK preps for vaccine R&D expansion, 200 hires for new global hub

9 years ago

Proteon triggers a stock implosion as its first PhIII proves to be a bust

9 years ago

First page Previous page 308 309 310311312 313 314 Next page Last page